Concepts (57)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Riluzole | 3 | 2021 | 6 | 1.290 |
Why?
|
| Griseofulvin | 1 | 2024 | 4 | 0.860 |
Why?
|
| Indoles | 1 | 2025 | 187 | 0.840 |
Why?
|
| Spinal Cord Injuries | 2 | 2021 | 69 | 0.670 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 18 | 0.580 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2018 | 92 | 0.570 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 20 | 0.540 |
Why?
|
| Plasma | 1 | 2017 | 38 | 0.530 |
Why?
|
| Nanoparticles | 1 | 2022 | 460 | 0.500 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2025 | 1766 | 0.420 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 1019 | 0.410 |
Why?
|
| Neoplasms | 1 | 2022 | 1377 | 0.340 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2024 | 140 | 0.330 |
Why?
|
| Polyethylene Glycols | 2 | 2022 | 108 | 0.320 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2024 | 241 | 0.290 |
Why?
|
| Reproducibility of Results | 3 | 2024 | 1081 | 0.280 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2025 | 388 | 0.270 |
Why?
|
| Rats | 3 | 2025 | 3735 | 0.270 |
Why?
|
| Spinal Cord | 2 | 2018 | 114 | 0.260 |
Why?
|
| Caco-2 Cells | 1 | 2025 | 64 | 0.240 |
Why?
|
| Solubility | 1 | 2025 | 139 | 0.230 |
Why?
|
| Microsomes, Liver | 1 | 2025 | 75 | 0.230 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2025 | 127 | 0.230 |
Why?
|
| Tissue Distribution | 1 | 2025 | 240 | 0.230 |
Why?
|
| Animals | 4 | 2025 | 16992 | 0.180 |
Why?
|
| Doxorubicin | 1 | 2022 | 97 | 0.180 |
Why?
|
| Liposomes | 1 | 2022 | 132 | 0.180 |
Why?
|
| Protein Binding | 1 | 2024 | 1082 | 0.160 |
Why?
|
| Drug Delivery Systems | 1 | 2022 | 277 | 0.160 |
Why?
|
| Male | 3 | 2025 | 23409 | 0.150 |
Why?
|
| Propylene Glycol | 1 | 2018 | 1 | 0.150 |
Why?
|
| Glycerol | 1 | 2018 | 34 | 0.140 |
Why?
|
| Neuroprotective Agents | 1 | 2021 | 269 | 0.140 |
Why?
|
| Solvents | 1 | 2018 | 113 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2018 | 260 | 0.140 |
Why?
|
| Calibration | 1 | 2017 | 63 | 0.130 |
Why?
|
| Acetates | 1 | 2017 | 32 | 0.130 |
Why?
|
| Biological Assay | 1 | 2017 | 63 | 0.130 |
Why?
|
| Limit of Detection | 1 | 2017 | 94 | 0.130 |
Why?
|
| Drug Design | 1 | 2018 | 186 | 0.130 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 465 | 0.130 |
Why?
|
| Humans | 4 | 2025 | 43102 | 0.110 |
Why?
|
| Brain | 1 | 2018 | 1472 | 0.080 |
Why?
|
| Quinidine | 1 | 2005 | 2 | 0.060 |
Why?
|
| Intestinal Absorption | 1 | 2005 | 22 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 4 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 30 | 0.040 |
Why?
|
| Half-Life | 1 | 2021 | 63 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 317 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1124 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 712 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 1857 | 0.030 |
Why?
|
| Furosemide | 1 | 2005 | 12 | 0.010 |
Why?
|
| Propranolol | 1 | 2005 | 18 | 0.010 |
Why?
|
| Hydrochlorothiazide | 1 | 2005 | 17 | 0.010 |
Why?
|
| Permeability | 1 | 2005 | 67 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 611 | 0.010 |
Why?
|